Centre de Recherche de l'Hôpital Maisonneuve-Rosemont, Montréal, QC, Canada.
Centre de Recherche de l'Hôpital Maisonneuve-Rosemont, Montréal, QC, Canada; Départment de Médecine, Université de Montréal, Montréal, QC, Canada.
Exp Hematol. 2014 Jul;42(7):526-35.e4. doi: 10.1016/j.exphem.2014.01.011. Epub 2014 Feb 3.
Leukemic stem cells share self-renewal properties and slow proliferation with hematopoietic stem cells. Based on expression signatures, it has been suggested that these cells use the same molecular pathways for these processes. However, it is not clear whether leukemic stem cells also respond to factors known to enhance the self-renewal activity of hematopoietic stem cells. The transcription factor homeobox B4 (HOXB4) is known to induce expansion of mouse hematopoietic stem cells. The recombinant TAT-HOXB4 protein also expands human CD34+ cells. In this study we investigated whether overexpression of HOXB4 could increase leukemic initiating cell numbers, an issue that is crucial to its clinical usage. A transgenic mouse model for E2A-PBX1 induced pre-B acute lymphoblastic leukemia was used in combination with HOXB4 transgenic mice to test oncogenic interactions between HOXB4 and E2A-PBX1. The frequency of leukemic initiating cells retrovirally overexpressing HOXB4 was measured by transplantation at limiting dilution and evaluation of leukemia development in recipient mice. Moreover, human B cell lines were evaluated for their colony forming cell potential upon exposure to TAT-HOXB4 protein. Our data with the mouse models show that HOXB4 neither accelerates the generation of E2A-PBX1 B cell leukemia nor expands the number of leukemia initiating cells. Additionally, the growth or colony forming cell proportions of human B cell lines was not changed by HOXB4, suggesting that human B leukemic initiating cells are not affected by HOXB4.
白血病干细胞与造血干细胞具有自我更新特性和缓慢增殖的特点。基于表达特征,有人提出这些细胞使用相同的分子途径来完成这些过程。然而,目前尚不清楚白血病干细胞是否也对已知能够增强造血干细胞自我更新活性的因素产生反应。转录因子同源盒 B4(HOXB4)已知可诱导小鼠造血干细胞的扩增。重组 TAT-HOXB4 蛋白也可扩增人 CD34+细胞。在这项研究中,我们研究了 HOXB4 的过表达是否可以增加白血病起始细胞的数量,这对于其临床应用至关重要。使用 E2A-PBX1 诱导前 B 急性淋巴细胞白血病的转基因小鼠模型与 HOXB4 转基因小鼠结合,以测试 HOXB4 与 E2A-PBX1 之间的致癌相互作用。通过移植到有限稀释度并评估受体小鼠的白血病发展来测量过表达 HOXB4 的白血病起始细胞的频率。此外,还评估了人类 B 细胞系在暴露于 TAT-HOXB4 蛋白时的集落形成细胞潜力。我们使用小鼠模型的数据表明,HOXB4 既不会加速 E2A-PBX1 B 细胞白血病的发生,也不会增加白血病起始细胞的数量。此外,HOXB4 未改变人 B 细胞系的生长或集落形成细胞比例,这表明人 B 白血病起始细胞不受 HOXB4 的影响。